SG11201805195YA - Composition comprising botulinum toxin - Google Patents

Composition comprising botulinum toxin

Info

Publication number
SG11201805195YA
SG11201805195YA SG11201805195YA SG11201805195YA SG11201805195YA SG 11201805195Y A SG11201805195Y A SG 11201805195YA SG 11201805195Y A SG11201805195Y A SG 11201805195YA SG 11201805195Y A SG11201805195Y A SG 11201805195YA SG 11201805195Y A SG11201805195Y A SG 11201805195YA
Authority
SG
Singapore
Prior art keywords
international
composition
frankfurt
pct
main
Prior art date
Application number
SG11201805195YA
Inventor
Klaus Fink
Harold Taylor
Hermann Russ
Peter Boderke
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of SG11201805195YA publication Critical patent/SG11201805195YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization M1111101110101011111 HO 11111 01110101111111011111101 I DIM III 11 International Bureau .. .... ..Yejd .... ...,,, (10) International Publication Number (43) International Publication Date WO 2017/148915 Al 8 September 2017 (08.09.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 38/48 (2006.01) A61Q 19/08 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 47/36 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP2017/054596 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 28 February 2017 (28.02.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 16158302.6 2 March 2016 (02.03.2016) EP (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: MERZ PHARMA GMBH & CO. KGAA GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [DE/DE]; Eckenheimer Landstr. 100, 60318 Frankfurt am TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Main (DE). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors: FINK, Klaus; Lindenallee 28, 50968 Köln DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (DE). TAYLOR, Harold; An den Drei Hohen 76, 60435 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Frankfurt am Main (DE). RUSS, Hermann; ZiircherstraBe GW, KM, ML, MR, NE, SN, TD, TG). — 37c, 8852 Altendorf SZ (CH). BODERKE, Peter; Bock- — enheimer Str. 3, 65824 Schwalbach (DE). Published: _ (74) Agents: GRAF KEYSERLINGK, Nikolai et al.; Ecken- — with international search report (Art. 21(3)) _ = heimer LandstraBe 100, 60318 Frankfurt am Main (DE). = = = = = = = = = = 1-1 kf) Il C:r GC 7r Il IN Il © (54) Title: COMPOSITION COMPRISING BOTULINUM TOXIN ei 0 (57) : The present invention concerns a composition comprising (a) botulinum toxin and (b) non-crosslinked hyaluronic ,...,.. acid and its use of the treatment or prevention of dystonia, spasticity and/or wrinkles. Further, the present invention relates to a method for cosmetically smoothing or preventing wrinkles comprising the step of administering the present composition.
SG11201805195YA 2016-03-02 2017-02-28 Composition comprising botulinum toxin SG11201805195YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16158302 2016-03-02
PCT/EP2017/054596 WO2017148915A1 (en) 2016-03-02 2017-02-28 Composition comprising botulinum toxin

Publications (1)

Publication Number Publication Date
SG11201805195YA true SG11201805195YA (en) 2018-07-30

Family

ID=55527275

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805195YA SG11201805195YA (en) 2016-03-02 2017-02-28 Composition comprising botulinum toxin

Country Status (12)

Country Link
EP (1) EP3423084B1 (en)
JP (2) JP2019507118A (en)
KR (1) KR20180114891A (en)
CN (1) CN108463242A (en)
AU (1) AU2017227978B2 (en)
BR (1) BR112018014445A2 (en)
CA (1) CA3010146A1 (en)
ES (1) ES2893838T3 (en)
MX (1) MX2018008855A (en)
RU (1) RU2743746C2 (en)
SG (1) SG11201805195YA (en)
WO (1) WO2017148915A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
CN109646673A (en) * 2017-10-12 2019-04-19 秀杰股份公司 The micro-structure preparation technique of botulin toxin
CN108992369B (en) * 2018-07-02 2021-07-30 山东天晟生物科技有限公司 Hyaluronic acid, preparation method and application thereof
WO2020056371A1 (en) * 2018-09-13 2020-03-19 Allergan, Inc. Clostridial toxin-hyaluronic acid compositions
WO2020069222A1 (en) * 2018-09-26 2020-04-02 Global Health Solutions Llc Topical neurotoxin compositions
CA3202665A1 (en) * 2020-12-18 2022-06-23 Sung Su Jang Pharmaceutical composition for long-term storage of liquid formulation of botulinum toxin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050094817A (en) * 2002-12-20 2005-09-28 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. Improved pharmaceutical botulinum toxin compositions
CA2578250C (en) * 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
US9044477B2 (en) 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
JP5722217B2 (en) * 2008-09-02 2015-05-20 アラーガン・ホールディングス・フランス・ソシエテ・パール・アクシオン・サンプリフィエＡｌｌｅｒｇａｎ Ｈｏｌｄｉｎｇｓ Ｆｒａｎｃｅ Ｓ．Ａ．Ｓ． Yarn of hyaluronic acid and / or its derivative, method for its preparation and use thereof
JP5688031B2 (en) * 2009-01-07 2015-03-25 ロバート ジョン ペトレラ， Treatment of soft tissue injury using hyaluronic acid and botulinum toxin
KR101453601B1 (en) * 2009-05-29 2014-10-22 갈데르마 리써어치 앤드 디벨로프먼트 Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
WO2011109130A1 (en) * 2010-03-01 2011-09-09 Tautona Group Lp Threads of hyaluronic acid and methods of use thereof
JP2012023637A (en) 2010-07-15 2012-02-02 Audio Technica Corp Noise cancel headphone
FR2966348B1 (en) * 2010-10-22 2012-11-09 Galderma Res & Dev COMPOSITIONS COMPRISING A WRINKLE FILLING MEDIUM AND A CHEMICALLY MODIFIED TETRACYCLINE
PT3241547T (en) * 2011-03-31 2020-08-26 Medy Tox Inc Lyophilized preparation of botulinum toxin
GB201219602D0 (en) 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins

Also Published As

Publication number Publication date
EP3423084B1 (en) 2021-09-01
AU2017227978B2 (en) 2022-03-10
CN108463242A (en) 2018-08-28
JP2019507118A (en) 2019-03-14
ES2893838T3 (en) 2022-02-10
BR112018014445A2 (en) 2018-12-11
RU2743746C2 (en) 2021-02-25
WO2017148915A1 (en) 2017-09-08
RU2018123197A (en) 2020-04-02
US20190060422A1 (en) 2019-02-28
RU2018123197A3 (en) 2020-04-13
KR20180114891A (en) 2018-10-19
EP3423084A1 (en) 2019-01-09
AU2017227978A1 (en) 2018-07-19
CA3010146A1 (en) 2017-09-08
JP2022130574A (en) 2022-09-06
MX2018008855A (en) 2018-11-29

Similar Documents

Publication Publication Date Title
SG11201805195YA (en) Composition comprising botulinum toxin
SG11201807195VA (en) Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
SG11201907034PA (en) Methods of treating influenza
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201900596XA (en) Cannabis composition
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201907435PA (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
SG11201900665VA (en) Cannabis composition
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201805755SA (en) Methods of administering hepcidin
SG11201810940XA (en) Methods of treating pancreatic cancer
SG11201806852PA (en) Protein purification
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201806127XA (en) Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate